UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

Annals of oncology, 2018-08, Vol.29 (8), p.1807-1813

2018

Volltextzugriff (PDF)

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

Annals of oncology, 2017-05, Vol.28 (5), p.1036-1041

2017

Volltextzugriff (PDF)

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

Annals of oncology, 2016-10, Vol.27 (10), p.1928-1940

2016

Volltextzugriff (PDF)

362 Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)

European journal of cancer (1990), 2015-09, Vol.51, p.S74-S75

2015

Volltextzugriff (PDF)

2801 Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a hase 1b study

European journal of cancer (1990), 2015-09, Vol.51, p.S558-S558

2015

Volltextzugriff (PDF)

500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028

European journal of cancer (1990), 2015-09, Vol.51, p.S102-S102

2015

Volltextzugriff (PDF)

2749 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity

European journal of cancer (1990), 2015-09, Vol.51, p.S546-S547

2015

Volltextzugriff (PDF)

502 Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028

European journal of cancer (1990), 2015-09, Vol.51, p.S103-S103

2015

Volltextzugriff (PDF)

506 Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer

European journal of cancer (1990), 2014-11, Vol.50, p.165-165

2014

Volltextzugriff (PDF)

A ph 1 study of 2 different schedules of the PSMA-tubulysin small-molecule drug conjugate EC1169 in pts with rec Met Cast-Resist PC (MCRPC)

Annals of oncology, 2015-03, Vol.26, p.ii16

2015

Volltextzugriff (PDF)

Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC): Study update

Annals of oncology, 2016-10, Vol.27, p.vi249-vi249

2016

Volltextzugriff (PDF)

Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study

Annals of oncology, 2016-10, Vol.27, p.vi247-vi247

2016

Volltextzugriff (PDF)

315O_PR Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study

Annals of oncology, 2015-12, Vol.26, p.ix93-ix93

2015

Volltextzugriff (PDF)

Identification of targetable cellular subsets within melanoma tumors

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.9082-9082

2009

Volltextzugriff (PDF)

Phase II trial of extended-dosing temozolomide in patients with melanoma

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.8531-8531

2007

Volltextzugriff (PDF)

Phase II trial of extended-dosing temozolomide in patients with melanoma

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.8042-8042

2006

Volltextzugriff (PDF)

Diagnostic dilemmas in oncology. Case 1. Melanoma metastatic to the testis

Journal of clinical oncology, 2000-09, Vol.18 (17), p.3187-3188

2000

Volltextzugriff (PDF)

In vitro and in vivo effects of sodium selenite on 7,12-dimethylbenz[a]anthracene-DNA adduct formation in isolated rat mammary epithelial cells

Carcinogenesis (New York), 1989-05, Vol.10 (5), p.823-826

1989

Volltextzugriff (PDF)

Diagnostic dilemmas in oncology

Journal of clinical oncology, 2000-09, Vol.18 (17), p.3187-3192

2000

Volltextzugriff (PDF)

Mapping the binding site of aflatoxin B1 in DNA: systematic analysis of the reactivity of aflatoxin B1 with guanines in different DNA sequences

Biochemistry (Easton), 1988-01, Vol.27 (1), p.472-481

1988

Volltextzugriff (PDF)

Mapping the binding site of aflatoxin B sub(1) in DNA: Systematic analysis of the reactivity of aflatoxin B sub(1) with guanines in different DNA sequences

Biochemistry (Easton), 1988-01, Vol.27 (1), p.472-481

1988

Volltextzugriff (PDF)

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

PloS one, 2017-12, Vol.12 (12), p.e0189848

2017

Volltextzugriff (PDF)

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

Journal of clinical oncology, 2017-12, Vol.35 (36), p.4050-4056

2017

Volltextzugriff (PDF)

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

British journal of cancer, 2020-05, Vol.122 (11), p.1630-1637

2020

Volltextzugriff (PDF)

Histopathologic Evolution of Melanocytes Associated With Rapid Clinical Progression of Melanoma: Clinicopathologic Presentation of Hyperprogressive Disease in a Patient Treated With Immunotherapy

The American journal of dermatopathology, 2022-12, Vol.44 (12), p.921-924

2022

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(51)

Sprache

Englisch
(51)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(14)
Humans
(12)
Oncology
(11)
Male
(8)
Female
(7)
Middle Aged
(7)
Tumors
(7)
Aged
(6)
Hematology, Oncology And Palliative Medicine
(6)
Patients
(6)
Adult
(5)
Biological And Medical Sciences
(4)
Immunotherapy
(4)
Melanoma
(4)
Solid Tumors
(4)
Aged, 80 And Over
(3)
Antibodies, Monoclonal, Humanized - Adverse Effects
(3)
Antineoplastic Agents, Immunological - Adverse Effects
(3)
Cancer Therapies
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

362 Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)

2801 Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a hase 1b study

500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028

2749 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity

502 Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028

506 Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer

A ph 1 study of 2 different schedules of the PSMA-tubulysin small-molecule drug conjugate EC1169 in pts with rec Met Cast-Resist PC (MCRPC)

Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC): Study update

Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study

315O_PR Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study

Identification of targetable cellular subsets within melanoma tumors

Phase II trial of extended-dosing temozolomide in patients with melanoma

Phase II trial of extended-dosing temozolomide in patients with melanoma

Diagnostic dilemmas in oncology. Case 1. Melanoma metastatic to the testis

In vitro and in vivo effects of sodium selenite on 7,12-dimethylbenz[a]anthracene-DNA adduct formation in isolated rat mammary epithelial cells

Diagnostic dilemmas in oncology

Mapping the binding site of aflatoxin B1 in DNA: systematic analysis of the reactivity of aflatoxin B1 with guanines in different DNA sequences

Mapping the binding site of aflatoxin B sub(1) in DNA: Systematic analysis of the reactivity of aflatoxin B sub(1) with guanines in different DNA sequences

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

Histopathologic Evolution of Melanocytes Associated With Rapid Clinical Progression of Melanoma: Clinicopathologic Presentation of Hyperprogressive Disease in a Patient Treated With Immunotherapy

Suchergebnisse filtern